Navigation Links
ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
Date:3/6/2009

LEUVEN, Belgium, March 6 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on innovative treatments for eye disease, vascular disease and cancer, today announces that it has completed patient enrolment for a Phase II trial of microplasmin intravitreal injection for the treatment of Diabetic Macular Edema (MIVI II DME). This trial is designed as the initial step in evaluating the utility of microplasmin in patients with diabetes, a group which is more prone to eye disease such as diabetic retinopathy, due to their underlying medical condition.

The MIVI II DME trial is a Phase II, randomized, double masked, sham injection controlled, dose ascending clinical trial evaluating the safety and initial efficacy of intravitreal microplasmin for the treatment of patients with Diabetic Macular Edema, a particular form of diabetic retinopathy. The trial is primarily intended to evaluate safety in this specific patient population, but will also assess efficacy by measuring the induction of posterior vitreous detachment (PVD). The trial recruited over 50 patients across Europe. Patients are to be followed for 12 months, with first unmasked data analyzed after 6 months follow-up, and to be presented towards the end of 2009.

Diabetic retinopathy is a major cause of visual loss and the leading cause of blindness in patients aged 20-60. Diabetic Macular Edema (DME) is a condition where swelling of the retina occurs in patients with diabetic retinopathy, due to a leakage of fluid from blood vessels within the macula. The only approved treatment for patients with DME is laser photocoagulation; however, this treatment does not improve vision once it is lost. In patients who do not respond to laser photocoagulation, vitrectomy (the surgical procedure used to produce a PVD) is currently used as a treatment, as vitreomacular adhesion is thought to play an important part in the
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
2. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
3. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
4. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
5. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
6. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
7. Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program
8. PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
9. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
10. Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
11. Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , February 27, 2015 ... new study showing you trends, R&D progress, and predicted ... heading? What are the commercial prospects for this ... you potential revenues and other trends to 2025, discussing ... report lets you assess regenerative medicine : cell-based ...
(Date:2/27/2015)... SAN DIEGO , Feb. 27, 2015 /PRNewswire/ ... three-dimensional biology company focused on delivering breakthrough 3D ... , President and Chief Executive Officer, will present ... "We invite you to join us for ... to provide updates on our commercial launch of ...
(Date:2/27/2015)... Feb. 27, 2015  Two mass spectrometry ... applications as their effectiveness is established, according ...  Kalorama Information says that while mass spectrometry ... powerful tool in proteomic biomarker discovery and ... its traditional techniques has struggled to elucidate ...
Breaking Medicine Technology:Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 3
... CHAPEL HILL, N.C., May 23 With increased ... generics in the,pharmaceutical market, marketing teams and science ... clinical trial results of new drugs in,development. With ... ones that do have to be spot on ...
... Coalition of Cancer Cooperative Groups sheds light on the ... on Grey,s Anatomy are not just ,do or die., ... episodes and,two-hour season finale of "Grey,s Anatomy" centered on ... doctors, the subject tops the,list of the country,s healthcare ...
Cached Medicine Technology:New Pharma Business Model Increases Pressure on Staff Communicating Trial Data 2The 'Anatomy' of Clinical Trials: 'Grey's' Season Finale Leaves Public in the Dark About the Myths and Realities 2The 'Anatomy' of Clinical Trials: 'Grey's' Season Finale Leaves Public in the Dark About the Myths and Realities 3
(Date:3/1/2015)... Birmingham, Clarkston, Lake Orion, Metamora, Michigan (PRWEB) March 01, 2015 ... BOTOX® , which is approved to treat Overactive Bladder (OAB) ... urgency and frequency in adults when another type of medication ... This is a different treatment option that takes another ... itself. , BOTOX® works on the nerves and ...
(Date:3/1/2015)... (PRWEB) March 01, 2015 Researchers say ... that so many sheet metal workers contract malignant mesothelioma. ... new report on its website. Click here to ... for Construction Research and Training monitored 17,345 sheet metal ... disproportionate number of them died of mesothelioma or ...
(Date:3/1/2015)... NY (PRWEB) March 01, 2015 The ... grown substantially over the past few weeks in two ... are actively filing claims, the Firm announces. , ... 7,713 cases in the Bergen County proceeding established for ... compared with a few weeks earlier, when 90 fewer ...
(Date:3/1/2015)... “ The Barrel Mill ” was featured on ... a look at the latest and coolest technology products and ... and a technology expert, conducted the review and shared with ... , According to Home Distillation of Alcohol, it's understood that ... a pretty cool product that’ll help anyone achieve a barrel ...
(Date:2/28/2015)... Malaysia (PRWEB) February 28, 2015 The ... all across Malaysia into one platform and gears towards ... , A series of group talks in smaller ... like Nation Building, Education, Personal Development, Leadership, Entrepreneurship, Healthcare, ... and raise awareness of Malaysian youths. , ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Now Offers BOTOX For Overactive Bladder Treatment 2Health News:New Study Finds Indirect Asbestos Exposure Can Raise Mesothelioma Risk for Sheet Metal Workers, According to Surviving Mesothelioma 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 3Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 4Health News:An Oak Infusion Spiral was Featured on NewsWatch Television on January 30, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4
... Recurring Revenue Growth of More Than ... ... Conference ... reported that due to the previously delayed European launch of,its partnered magnetic irrigated catheter, and the ...
... Jan. 15 The Wisconsin Physicians Service,Insurance Corporation (WPS) ... Health Care from interfering with WPS,s contractual,relationship with HealthEOS ... HealthEOS to abide by the terms of its contract ... by WPS to meet face,to face with Aurora and ...
... HHS, Agency for,Healthcare Research and Quality today announced a ... government, and state Medicaid,agencies as they consider consumer financial ... quality of health care and get better,value for what ... either a reward offered to influence,patients to behave in ...
... small molecules used by cells to control the proteins ... patients who are likely to respond poorly to therapy. ... of acute myeloid leukemia (AML) and could lead to ... study examined the levels of molecules called microRNAs in ...
... waiting more, study finds, , , TUESDAY, Jan. 15 (HealthDay News) ... emergency room when you,ve got crushing chest pain or can,t ... get treatment. , Unfortunately, in too many instances, that,s exactly ... in emergency rooms have increased by 36 percent for all ...
... of Ophthalmology and Visual Sciences at University Hospitals Case ... awarded $110,000 in unrestricted funds by Research to Prevent ... , Under the direction of Jonathan ... in excess of $1.6 million over the past 11 ...
Cached Medicine News:Health News:Stereotaxis Provides Fourth Quarter 2007 Revenue Outlook 2Health News:Stereotaxis Provides Fourth Quarter 2007 Revenue Outlook 3Health News:Stereotaxis Provides Fourth Quarter 2007 Revenue Outlook 4Health News:Wisconsin Physicians Service Insurance Corporation Files Suit Against Aurora Health Care and HealthEOS 2Health News:AHRQ Releases Consumer Financial Incentives Guide for Employers and Other Health Care Purchasers 2Health News:AHRQ Releases Consumer Financial Incentives Guide for Employers and Other Health Care Purchasers 3Health News:Molecules might identify high-risk acute-leukemia patients 2Health News:ER Wait Times Getting Longer 2Health News:ER Wait Times Getting Longer 3Health News:ER Wait Times Getting Longer 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: